CEL-SCI (NYSE:CVM) Cut to “Sell” at StockNews.com

CEL-SCI (NYSE:CVM) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

CEL-SCI Stock Up 13.4 %

Shares of CEL-SCI stock opened at $0.64 on Wednesday. The company’s fifty day simple moving average is $0.95 and its two-hundred day simple moving average is $1.13. CEL-SCI has a 12-month low of $0.54 and a 12-month high of $3.23. The company has a current ratio of 0.64, a quick ratio of 0.18 and a debt-to-equity ratio of 1.00. The company has a market cap of $40.83 million, a P/E ratio of -1.10 and a beta of 0.69.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in CEL-SCI by 5.5% in the first quarter. Vanguard Group Inc. now owns 2,193,327 shares of the company’s stock worth $4,189,000 after purchasing an additional 113,703 shares during the period. Plotkin Financial Advisors LLC bought a new position in shares of CEL-SCI in the 3rd quarter worth about $98,000. Thoroughbred Financial Services LLC increased its stake in shares of CEL-SCI by 140.9% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock worth $158,000 after acquiring an additional 80,001 shares in the last quarter. Geode Capital Management LLC lifted its position in CEL-SCI by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after acquiring an additional 53,879 shares during the period. Finally, Calton & Associates Inc. bought a new position in CEL-SCI during the 3rd quarter valued at approximately $50,000. Institutional investors own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.